Cognetivity Neurosciences confirms first Middle East deployment in state-of-the-art Clemenceau Medical Center in Dubai

(Vancouver, B.C.) - Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity") (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) announced that it has reached its first commercial agreement for the Integrated Cognitive Assessment (ICA) to be deployed in clinical care in the Middle East.

Following Cognetivity's launch in the region only several weeks ago, the ICA is now set to be deployed at the state-of-the-art Clemenceau Medical Center (CMC) in Dubai. CMC in Dubai is situated within the renowned Dubai Healthcare City and enjoys a reputation as one of the region's leading hospitals across a range of medical specialities. It forms part of the prestigious Clemenceau Medicine International network, which is closely affiliated with Johns Hopkins Medicine International.

The CMC network is committed to making use of cutting-edge developments in medical technology, including artificial intelligence (AI), to provide its patients with the best possible care. Its flagship hospital, CMC in Beirut, was recently named in Newsweek's 2021 list of the top 100 smart hospitals in the world, ranking highest across the Middle East.

As part of the center's commitment to innovation and patient-first medical excellence, the ICA will be used to enhance the timely detection of mild cognitive impairment (MCI) and dementia. The ICA is perfectly placed to drive improvements in clinical cognitive assessment and monitoring thanks to its high sensitivity to early-stage deterioration and avoidance of learning effects upon repeat testing. Crucially, the test is language-independent and free from educational or cultural bias, facilitating its rapid deployment in new environments as a globally-applicable tool.

The implementation will be overseen by neurologist and clinical neurophysiologist Dr Raja Sawaya. One of the most highly respected clinicians, educators and researchers in his field throughout the Middle East, Dr Sawaya is also a Professor of Neurology and Clinical Neurophysiology at the American University of Beirut Medical Center. He is a fellow and active member of the American Academy of Neurology and the American Academy of Electrodiagnostic Medicine.
Commenting on the announcement, Dr Sawaya said: "Dementia is a serious and growing healthcare problem all over the world, including the Middle East. The ICA offers hope as a cutting-edge technology that can drive great improvements in the quality and efficiency of cognitive assessment, particularly at the all-important earlier stages of disease. I'm really excited to see the difference it makes for our patients, and can already see further areas for its application on the back of this rollout."

Mazen Sobh, Vice President (Business Development) at Cognetivity, said: "It's fantastic to be bringing the ICA to clinical care in Dubai for the first time. There is clearly an urgent, unmet need for much better cognitive assessment tools in the region, as throughout so much of the world – it represents a brilliant opportunity for us and this is a very welcome first step."

Dr Sina Habibi, Cognetivity's CEO, also said: "We're thrilled about the deployment, which will see the ICA form part of a cutting-edge service dedicated to providing world-leading healthcare. Achieving this feat within a few short weeks of our regional launch proves that we have got it absolutely right in terms of recognising the clinical demand but also creating a world-beating tool whose language- and culture-independence make it rapidly deployable in any new clinical environment. This stands us in very good stead as we continue to pursue our ambitions of large-scale, global commercial rollout."

PRINT THIS ARTICLE